Allergy Therapeutics PLC has made an amendment to its Open Offer Circular, stating that the Open Offer is an invitation to qualifying shareholders to acquire 689,102,532 Open Offer Shares at a price of 1 pence per share. The Open Offer is being made on the basis of 6 Open Offer Shares for every 1 Existing Ordinary Share held by qualifying shareholders on the Record Date. The Circular will be available to qualifying shareholders on the company's website.

In addition, Allergy Therapeutics has entered into an amendment to its Facility Agreement with Southern Fox and SkyGem Acquisition. The amendment, called the Extension Facility, allows the company to draw an additional total principal sum of up to £15 million on an uncommitted basis. The Extension Facility must be repaid in full by December 31, 2025. To provide security for any amounts drawn under the Extension Facility, the existing security package under the Facility Agreement will remain in place, and a supplemental English law security will be granted.